» Articles » PMID: 16138222

Changes in Clinical and Laboratory Findings at the Time of Diagnosis of Primary Hyperparathyroidism in a University Hospital in São Paulo from 1985 to 2002

Overview
Date 2005 Sep 3
PMID 16138222
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

In contrast to most developed countries, most patients with primary hyperparathyroidism in Brazil are still symptomatic at diagnosis. However, we have been observing a change in this pattern, especially in the last few years. We evaluated 104 patients, 77 females and 27 males aged 11-79 years (mean: 54.4 years), diagnosed between 1985 and 2002 at a University Hospital. Diagnosis was made on the basis of clinical findings and of high total and/or ionized calcium levels, high or inappropriate levels of intact parathyroid hormone and of surgical findings in 80 patients. Patients were divided into three groups, i.e., patients diagnosed from 1985 to 1989, patients diagnosed from 1990 to 1994, and patients diagnosed from 1995 to 2002. The number of new cases diagnosed/year increased from 1.8/year in the first group to 6.0/year in the second group and 8.1/year in the third group. The first group comprised 9 patients (mean serum calcium +/- SD, 13.6 +/- 1.6 mg/dl), 8 of them (88.8%) defined as symptomatic. The second group comprised 30 patients (mean calcium +/- SD, 12.2 +/- 1.63 mg/dl), 22 of them defined as symptomatic (73.3%). The third group contained 65 patients (mean calcium 11.7 +/- 1.1 mg/dl), 34 of them symptomatic (52.3%). Patients from the first group tended to be younger (mean +/- SD, 43.0 +/- 15 vs 55.1 +/- 14.4 and 55.7 +/- 17.3 years, respectively) and their mean serum calcium was significantly higher (P < 0.05). All of symptomatic patients independent of group had higher serum calcium levels (12.4 +/- 1.53 mg/dl, N = 64) than asymptomatic patients (11.4 +/- 1.0 mg/dl, N = 40). Our data showed an increase in the percentage of asymptomatic patients over the years in the number of primary hyperparathyroidism cases diagnosed. This finding may be due to an increased availability of diagnostic methods and/or to an increased awareness about the disease.

Citing Articles

PTH immunoassay interference: differential diagnosis with normocalcemic primary hyperparathyroidism?.

Ohe M, Takimoto R, Ferrer C, Viana Lima J, Biscolla R, Vieira J Arch Endocrinol Metab. 2024; 68:e230315.

PMID: 39529983 PMC: 11554362. DOI: 10.20945/2359-4292-2023-0315.


Surgery for primary hyperparathyroidism.

Neves M, Santos R, Ohe M Arch Endocrinol Metab. 2022; 66(5):678-688.

PMID: 36382757 PMC: 10118824. DOI: 10.20945/2359-3997000000557.


Epidemiology, Pathophysiology, and Genetics of Primary Hyperparathyroidism.

Minisola S, Arnold A, Belaya Z, Brandi M, Clarke B, Hannan F J Bone Miner Res. 2022; 37(11):2315-2329.

PMID: 36245271 PMC: 10092691. DOI: 10.1002/jbmr.4665.


Reduced fracture incidence in patients having surgery for primary hyperparathyroidism.

Nilsson M, Stahl E, Akesson K, Thier M, Nordenstrom E, Almquist M Clin Endocrinol (Oxf). 2022; 97(3):276-283.

PMID: 35192220 PMC: 9545002. DOI: 10.1111/cen.14703.


Mortality after surgery for primary hyperparathyroidism: results from a nationwide cohort.

Nilsson M, Ivarsson K, Thier M, Nordenstrom E, Bergenfelz A, Almquist M Br J Surg. 2021; 108(7):858-863.

PMID: 33842935 PMC: 10364903. DOI: 10.1093/bjs/znab017.